Nebula Biocides receives millions in seed funding
Greifswald — Great success for Nebula Biocides GmbH, three investors decide to invest in the Greifswald-based start-up. This brings the start-up a significant step closer to its goal of obtaining approval for and launching the highly effective disinfectant Sporosan® on the market.
With a total investment of 1.6 million euros, the start-up Nebula Biocides, founded in 2019, can now take off: the approval of the novel disinfection process Sporosan® is supported by High-Tech Gründerfonds (HTGF), Mittelständische Beteiligungsgesellschaft Mecklenburg-Vorpommern mbH (MBMV) and a strategic investor from the cleaning and disinfection equipment sector as part of a seed financing.
“We are very pleased to have a strong business partner and, with HTGF and MBMV, two experienced and network-strong financial investors on board,” said Dr. Jörn Winter, CEO of Nebula Biocides
Together with his colleague Dr. Ansgar Schmidt-Bleker, also founder and managing director of Nebula Biocides GmbH, he had discovered the novel disinfection process in 2016. As part of their work at the Leibniz Institute for Plasma Research and Technology e.V. (INP), the physicists identified the substance peroxinitrite acid as an effective agent and developed the Sporosan® process on this basis. In this process, two starting components react with each other for a short time and have a highly disinfecting effect during this period.
Sporosan® not only kills bacteria and viruses; even stubborn bacterial spores have no chance of survival thanks to the new process,” says Schmidt-Bleker, emphasizing the broad efficacy of the disinfectant. In the future, this will also prevent infections with the dangerous hospital germ Clostridioides difficile, which leads to severe diarrhea and is often fatal, especially in previously ill patients. The Greifswald researchers have thus achieved a breakthrough — to date there is no disinfectant in the world with a comparably strong and rapid effect that is at the same time environmentally friendly and gentle in use.
The significance and potential of the active ingredient were also recognized by the three investors, whose participation will now make it possible to finance the studies required for approval.
“We are very proud to welcome Nebula Biocides to our portfolio with their distinctly disruptive chemistry innovation. The underlying technology promises to create numerous sustainable application opportunities,” Dr. Nikolaus Raupp, Investment Manager at High-Tech Gründerfonds
With the help of the investors, the company, which now consists of a team of five, can pursue two paths at once: First, it is aiming for approval as a biocide, so that Sporosan will be available to everyone as a hand and surface disinfectant from 2028. In parallel, the Nebula team is working intensively on solutions for the sporicidal reprocessing of medical devices with the aim of marketing the disinfectant itself as a medical device. With the strategic investor, an industrial partner has already been found who would like to use Sporosan® for its products; market launch is expected in 2024. However, the start-up is already receiving inquiries from other interested companies from a wide range of industries every week, which only further underscores the scope of Greifswald’s innovation in the healthcare, pharmaceutical and food industries.
About Nebula Biocides GmbH
Nebula Biocides GmbH was founded in 2019 as a spin-off from the Leibniz Institute for Plasma Science and Technology e.V. (INP) by the scientists Dr. Jörn Winter, Dr. Ansgar Schmidt-Bleker and the director of INP Prof. Dr. Klaus-Dieter Weltmann in Greifswald. With the aim of providing comprehensive protection against infectious agents, the company develops application-oriented disinfection solutions that reliably kill not only bacteria and viruses but also stubborn bacterial spores. www.nebula-biocides.de
About Mittelständische Beteiligungsgesellschaft Mecklenburg-Vorpommern mbH
Mittelständische Beteiligungsgesellschaft Mecklenburg-Vorpommern mbH (MBMV) has been supporting regional SMEs with project financing for over 28 years. It closes financing gaps and at the same time puts the equity base of small and medium-sized enterprises on a broader footing and makes it possible to realize promising ideas or promising business strategies. MBMV is also a reliable partner for start-ups and entrepreneurs. www.mbm‑v.de